Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMB9IPR)

Drug Name
RS-504393 Drug Info
Synonyms
300816-15-3; RS 504393; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; RS-504393; RS504393; CHEMBL134074; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; 6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one; ACMC-20a25e; GTPL781; SCHEMBL9972645; CTK4G4374; CHEBI:93525; DTXSID20433290; MolPort-021-804-998; BCPP000086; HMS3269M19; BCP02713; ZINC13527116; ABP000463
Cross-matching ID
PubChem CID
9953769
ChEBI ID
CHEMBL134074
CAS Number
CAS 300816-15-3
TTD Drug ID
D0X4SI

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.49 0.00e+0 19/20 (95%) MSMO1;SQLE;DHCR24;...
Terpenoid backbone biosynthesis 2.45 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;ACAT2;...
Valine, leucine and isoleucine degradation 2.26 0.00e+0 42/48 (87.5%) HMGCS1;ACAT2;ACAT1;...
Pyruvate metabolism 2.16 0.00e+0 41/47 (87.23%) ACAT2;ACACA;ACAT1;...
Glyoxylate and dicarboxylate metabolism 2.15 0.00e+0 23/30 (76.67%) ACAT2;ACAT1;ACO1;...
Synthesis and degradation of ketone bodies 2.12 0.00e+0 9/10 (90%) HMGCS1;ACAT2;ACAT1;...
Peroxisome 2.07 0.00e+0 72/82 (87.8%) IDH1;AMACR;ECH1;...
Fatty acid elongation 2.07 1.19e-3 19/27 (70.37%) ELOVL6;ACOT7;HACD3;...
Biosynthesis of unsaturated fatty acids 2.06 2.12e-3 21/27 (77.78%) SCD;FADS1;ELOVL6;...
Fatty acid degradation 2.06 1.91e-3 40/43 (93.02%) ACAT2;ACSL3;ACSL1;...
PPAR signaling pathway 2.04 1.73e-3 66/74 (89.19%) HMGCS1;SCD;DBI;...
Butanoate metabolism 2.02 3.18e-3 23/28 (82.14%) HMGCS1;ACAT2;ACAT1;...
Propanoate metabolism 1.97 4.40e-3 30/34 (88.24%) ACAT2;ACACA;ACAT1;...
Cortisol synthesis and secretion 1.95 4.77e-3 58/65 (89.23%) LDLR;PLCB1;GNA11;...
Vibrio cholerae infection 1.94 4.45e-3 44/50 (88%) ATP6V0E2;KDELR3;ATP6AP1;...
Sulfur metabolism 1.87 7.15e-3 9/10 (90%) TST;PAPSS2;MPST;...
Citrate cycle (TCA cycle) 1.87 6.73e-3 30/30 (100%) IDH1;ACLY;ACO1;...
Fatty acid biosynthesis 1.86 6.89e-3 16/18 (88.89%) FASN;ACACA;ACSL3;...
Ascorbate and aldarate metabolism 1.85 7.03e-3 15/30 (50%) AKR1A1;UGT2B28;UGT2B4;...
Drug metabolism 1.85 6.68e-3 78/151 (51.66%) DPYS;GSTA4;CES2;...
Pentose phosphate pathway 1.84 7.27e-3 25/30 (83.33%) ALDOC;ALDOB;FBP1;...
Tryptophan metabolism 1.83 7.80e-3 35/42 (83.33%) ACAT2;ACAT1;AOC1;...
Glutamatergic synapse 1.83 7.46e-3 97/114 (85.09%) SLC1A1;PLCB1;GNAI1;...
Glycolysis / Gluconeogenesis 1.82 8.35e-3 56/67 (83.58%) ALDOC;ALDOB;AKR1A1;...
Primary bile acid biosynthesis 1.80 1.11e-2 15/17 (88.24%) AMACR;ACOX2;SLC27A5;...
Metabolism of xenobiotics by cytochrome P450 1.76 1.32e-2 49/77 (63.64%) GSTA4;HSD11B1;AKR7A3;...
Renin-angiotensin system 1.76 1.31e-2 20/23 (86.96%) MME;AGTR1;REN;...
AMPK signaling pathway 1.67 3.30e-2 106/120 (88.33%) SCD;HMGCR;FASN;...
Retinol metabolism 1.66 3.26e-2 41/68 (60.29%) RDH11;UGT2B28;AOX1;...
Cholinergic synapse 1.65 3.75e-2 99/113 (87.61%) PLCB1;GNA11;GNAI1;...
Viral myocarditis -1.61 4.11e-2 53/60 (88.33%) CASP9;HLA-DQB1;BID;...
Kaposi sarcoma-associated herpesvirus infection -1.61 4.14e-2 172/193 (89.12%) MTOR;BAX;CREBBP;...
Cytosolic DNA-sensing pathway -1.62 3.94e-2 52/63 (82.54%) DDX58;IRF7;IKBKE;...
Th17 cell differentiation -1.65 3.23e-2 95/107 (88.79%) FOS;IFNGR1;MAPK10;...
Primary immunodeficiency -1.66 2.98e-2 33/38 (86.84%) AICDA;CD3D;ZAP70;...
Spliceosome -1.68 2.62e-2 101/150 (67.33%) CTNNBL1;HNRNPA1;DDX23;...
Colorectal cancer -1.68 2.73e-2 84/86 (97.67%) BRAF;TCF7L2;TGFB1;...
T cell receptor signaling pathway -1.68 2.80e-2 93/104 (89.42%) FOS;DLG1;NCK2;...
Human T-cell leukemia virus 1 infection -1.68 2.84e-2 197/219 (89.95%) TERT;ANAPC5;VDAC2;...
Graft-versus-host disease -1.71 2.23e-2 32/42 (76.19%) CD86;HLA-DOB;CD28;...
Herpes simplex virus 1 infection -1.71 2.35e-2 165/498 (33.13%) DDX58;IRF7;CASP9;...
FoxO signaling pathway -1.71 2.36e-2 118/131 (90.08%) IL10;PRMT1;BRAF;...
Allograft rejection -1.71 2.50e-2 32/38 (84.21%) CD86;HLA-DOB;CD28;...
Systemic lupus erythematosus -1.72 2.53e-2 45/135 (33.33%) CD86;SNRPB;HLA-DOB;...
Chronic myeloid leukemia -1.72 2.55e-2 72/76 (94.74%) IKBKG;BRAF;TGFB1;...
Viral protein interaction with cytokine and cytokine re... -1.77 1.67e-2 84/100 (84%) CCL8;TNFRSF10B;CXCL5;...
Asthma -1.77 1.55e-2 25/31 (80.65%) HLA-DOB;CD40;CD40LG;...
MicroRNAs in cancer -1.78 1.68e-2 146/310 (47.1%) EGFR;BMPR2;MTOR;...
TNF signaling pathway -1.79 1.84e-2 103/112 (91.96%) LTA;CASP3;JAG1;...
Measles -1.87 7.45e-3 133/139 (95.68%) CSNK2A1;CDK2;MAPK8;...
Intestinal immune network for IgA production -1.89 8.27e-3 38/48 (79.17%) CD86;AICDA;HLA-DOB;...
Epstein-Barr virus infection -1.89 9.31e-3 189/202 (93.56%) HDAC2;CDK2;MAPK8;...
Autoimmune thyroid disease -1.93 7.60e-3 46/53 (86.79%) CD86;TSHR;HLA-DOB;...
Cell cycle -1.95 7.09e-3 110/124 (88.71%) ORC2;STAG2;SMC3;...
Small cell lung cancer -1.98 8.51e-3 90/92 (97.83%) ITGA3;TRAF2;ITGA2B;...
p53 signaling pathway -1.98 1.06e-2 63/73 (86.3%) CDK2;CASP9;PIDD1;...
RNA transport -1.99 1.06e-2 128/186 (68.82%) THOC1;NUP205;EIF5B;...
IL-17 signaling pathway -2.11 5.32e-3 84/94 (89.36%) TRAF3;CXCL6;TBK1;...
Ribosome biogenesis in eukaryotes -2.26 0.00e+0 52/108 (48.15%) CSNK2A1;RPP40;NXT2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H